ECCO 2025

Eating is part of life – and of special therapeutic…

Surgical approaches in IBD – all questions solved?

Personalized dosing of infliximab in moderate to severe…

The importance of endoscopic surveillance – current…

Comparative efficacy between biologics in UC – the need…

New UC-kids on the block: a IL7 receptor antagonist &…

The perfect dosing of our drugs – data on ustekinumab…

Urgency – what is hen and what is egg?

Combination therapies – on the way to the holy grail?

Old vs. new – ustekinumab vs. modern IL23

Comparative efficacy and safety – do we need to…

What is the best treatment goal for moderate to severe…

Kono-S anastomosis is not superior to side-to-side…

Subcutaneous therapy with guselkumab for Crohn's…

Autologous HSCT – still an option for refractory CD?

Subcutaneous induction with guselkumab in CD is…

The need for early treatment in Crohn’s disease – a…

Early CD treatment with vedolizumab

Subkutane Therapie mit Guselkumab bei Morbus Crohn und…

La anastomosis Kono-S no es superior a la anastomosis…

HSCT autologue – toujours une option pour la maladie de…

Personalized dosing in acute UC

First combination of upadacitinib and vedolizumab in…

Obefazimod maintenance treatment: a new approach

How to treat UC patients after failure of a s.c.…

Long-term efficacy and safety of a lower obefazimod…

Appendectomy – a good option for UC

Erste Kombination von Upadacitinib und Vedolizumab bei…

Subkutane Therapie mit Guselkumab bei Morbus Crohn und…

Long-term efficacy and safety of a lower obefazimod…

Obefazimod in der Erhaltung: Neuer Ansatz

Appendektomie – eine gute Option bei Colitis Ulcerosa

SOR102 – a novel oral bispecific antibody in patients…

New treatments – fast forward to the future

New mode of action for treating UC

s.c.? i.v.? Just swallow it! News from the oral…

A new class of drugs: anti-TL1A antibodies

s.c.? i.v.? Einfach schlucken! Neues vom oralen…

Nouveau mode d'action pour le traitement de la RCH

טיפולים חדשים- fast forward לעתיד

Eine neue Substanzklassen: Anti-TL1A Antikörper

SOR102 – un nuovo anticorpo bispecifico orale in…

Comprehensive approach necessary to treat our patients…

Mirikizumab demonstrates rapid improvements in bowel…

Association between histologic response and…

Minimal Residual Disease: a new treatment goal in IBD?

What is the best treatment goal for moderate to severe…

גישה כוללנית הכרחית לטיפול בחולים בדרך המיטבית

Was ist der beste Therapieendpunkt bei moderater bis…

Minimal Residual Disease: ein neuer Endpunkt bei CED?

Definiendo la curación radiológica en enfermedad de…

Fibre consumption and the risk of developing CD

A low emulsifier diet is a treatment for moderate to…

Tasty&Healthy – the next step towards anti-inflammatory…

Spożycie błonnika a ryzyko zachorowania na chorobę…

ASTRO study established the efficacy of guselkumab…

Comparative efficacy of infliximab and vedolizumab…

PODIUM: effectiveness & safety of 2nd line vedolizumab…

Etrasimod improves clinical, endoscopic and histologic…

Eficacia comparativa de infliximab vs. vedolizumab tras…

PODIUM: efficacia e sicurezza di Vedolizumab o…

Efficacia e sicurezza di una terapia combinata avanzata…

Dose escalation of primary non-responders is not…

Optimizing biologics in CD – is it relevant for all?

Infliximab induction fails to reach target drug level…

Effectiveness & safety of advanced combination therapy…

Mancato aumento dei livelli terapeutici di IFX nella…

Efficacia e sicurezza di una terapia combinata avanzata…

אופטימיזציה של תכשירים ביולוגים במחלת קרוהן-האם מתאים…

Psychological factors and the risk of IBD flare

Rischio di IMID associato al trattamento con anti-TNF e…

αvβ6 – new biomarker in prediciting, staging and…

Comment détecter les lésions prénéoplasiques par…

Identification of CD and UC specific clonotypes

סיווג HLA-התקדמות בטיפול מותאם אישית?